Expert Interview
Discussing Heron Therapeutics’ APONVIE (aprepitant / HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV), following FDA Approval
Ticker(s): HRTXAn anesthesiologist with experience in PONV.
Please describe your clinical trial practice,how many patients do you prescribe treatment for Postoperative Nausea and Vomiting, what is the standard of care?
Added By: slingshot_insightsCould you please comment on the rationale behind using P/neurokinin-1 (NK1) receptor antagonists in PONV?
Please discuss the results that the approval is based on-single 32mg 30-second IV injection, APONVIE reaches drug levels associated with ≥97% receptor occupancy in the brain within five minutes and maintains therapeutic plasma concentrations for at least 48 hours. -Treatment with aprepitant resulted in approximately 50% fewer patients vomiting in the first 24 and 48 hours compared to ondansetron. How convincing are those results to you?
Since the drug’s first approval in 2006 for use following chemotherapy to alleviate nausea and vomiting, how well has aprepitant been received by the medical practitioners? How often is it used, and what are the pros and cons, if any?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
